Inactive Instrument

Press Releases ORCHAR Nasdaq

Equities

US68570P1012

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

FDA Approves First Gene Therapy To Treat Children With Metachromatic Leukodystrophy	Apr. 03	AQ
FDA approves innovative gene therapy for MLD	Mar. 20	AQ
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy	Mar. 20	AQ
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.	Mar. 18	AQ
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome	Feb. 05	AQ
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium	Feb. 02	AQ
Kyowa Kirin Co., Ltd - Notice regarding Completion of Share Acquisition of Orchard Therapeutics plc	Jan. 26	AQ
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy	Jan. 25	AQ
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases	Jan. 24	AQ
Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD	Dec. 11	AQ
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH	Nov. 30	AQ
ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX	Nov. 28	BU
Mucopolysaccharidosis Type I Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 16	AQ
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments	Nov. 13	AQ
Wiskott Aldrich Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 07	AQ
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023	23-10-26	AQ
Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023	23-10-24	AQ
Metachromatic Leukodystrophy Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	23-10-09	AQ
ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX	23-10-06	BU
ORTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Orchard Therapeutics plc Is Fair to Shareholders	23-10-05	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ORCHAR Nasdaq

Equities

US68570P1012

Press Releases

Filters